Loading
NASDAQHealthcareBiotechnology
Latest quote
$95.01
+$2.25 · +2.43%
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Latest quote
$95.01
+$2.25 · +2.43%
After-hours
$95.01
$0.00 · 0.00%
Oct 9, 4:04 PM ET
Regular session · ET · Market data may be delayed.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Day range
Current $95.01
52-week range
Current $95.01
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
61
Bullish
Risk
81
Extreme Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Day range
Current $95.01
52-week range
Current $95.01
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.3M USD | 200K USD | 1.8M USD | 2.19M USD | 7.13M USD |
| Cost of goods sold | 2.48M USD | 2.29M USD | 1.19M USD | 110.19M USD | 2.69M USD |
| Gross profit | −1.18M USD | −2.09M USD | 609K USD | −107.99M USD | 4.44M USD |
| Research and development | 113.03M USD | 203.74M USD | 190.65M USD | 110.19M USD | 71.44M USD |
| Selling, general, and administrative | 23.3M USD | 127.91M USD | 29.38M USD | 21.12M USD | 9.67M USD |
| Operating expenses | 133.84M USD | 329.36M USD | 219.83M USD | 21.12M USD | 81.11M USD |
| Interest income | 7.55M USD | 10.94M USD | 11.92M USD | — | — |
| Interest expense | 12.2M USD | 13.49M USD | 31.84M USD | 16.11M USD | 5.22M USD |
| Depreciation and amortization | 2.48M USD | 2.29M USD | 1.19M USD | 1.23M USD | 1.2M USD |
| Operating income | −135.03M USD | −331.45M USD | −219.22M USD | −129.12M USD | −76.67M USD |
| Net income | −140.06M USD | 1.69B USD | −241.36M USD | −145.23M USD | −81.77M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 30, 2024 | $0.85Irregular | May 30, 2024 | Jun 20, 2024 |
Ex-dividend May 30, 2024
$0.85
Irregular
Record May 30, 2024 · Payment Jun 20, 2024
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI46.83M0.00%2.3T USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI31.26M0.31%10.11B USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM23.38M0.03%77.7B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF14.2M0.01%95.4B USD0.05%$235+0.80%
iShares Biotechnology ETFIBB7.9M0.08%10.41B USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO6.92M0.04%18B USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO6.65M0.05%14.04B USD0.24%$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA4.9M0.02%21.73B USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
